SE 175
目录号 : GC16204
A nitric oxide donor intended for in vivo use
Cas No.:258278-64-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
SE 175 is a NO donor.
Nitric oxide (NO) mediates various physiological and pathophysiological processes in the cardiovascular system. Pharmacological compounds releasing NO are useful tools for evaluating the critical role of NO in cardiovascular physiology and therapeutics. These NO donors constitute two broad classes of compounds, those releasing NO and those requiring enzymatic metabolism to generate NO.
In vitro: SE 175 was identified as an organic nitrate donor of the same class as nitroglycerin, which acted as NO-donors following reductive transformation of the nitrate group to nitric oxide. SE 175 and other nitroxyacylated thiosalicylates were developed in an effort to facilitate such reductive process and accelerate the release of NO. SE 175 was found to be stable in buffer or saline solution. In addition, SE 175 was able to stimulate endothelial soluble guanylate cyclase and induce aortic vasorelaxation with an EC50 of 20 μM, which was intermediate in potency between isosorbide dinitrate and nitroglycerine [1].
In vivo: Up to now, there is no animal in vivo data reported.
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Endres, S. ,Hacker, A.,Noack, E., et al. NO-donors, Part 3: Nitrooxyacylated thiosalicylates and salicylates-synthesis and biological activities. European Journal of Medicinal Chemistry 34, 895-901 (1999).
| Cas No. | 258278-64-7 | SDF | |
| 化学名 | 2-[[4-[(nitrooxy)methyl]benzoyl]thio]-benzoic acid, methyl ester | ||
| Canonical SMILES | COC(=O)c1ccccc1SC(=O)c1ccc(CO[N](=O)O)cc1 | ||
| 分子式 | C16H13NO6S | 分子量 | 347.3 |
| 溶解度 | ≤11mg/ml in ethanol;35mg/ml in DMSO;50mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8794 mL | 14.3968 mL | 28.7936 mL |
| 5 mM | 0.5759 mL | 2.8794 mL | 5.7587 mL |
| 10 mM | 0.2879 mL | 1.4397 mL | 2.8794 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。